All In Biotech

Drug Trial Radar · NCT06005428

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

A Phase 2A, Investigator & Subject Blinded, Sponsor Unblinded, Placebo-Controlled, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia

Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

7

Actual

Start

Nov 7, 2023

Primary completion

May 31, 2025

Study completion May 31, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate in a 3-period, randomized 2-sequence study. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo, with each study drug administered as a single dose.

Conditions

  • CPVT1
  • Heart Defects, Congenital
  • Heart Diseases
  • Ventricular Tachycardia

Interventions

  • CRD-4730Drug

    Oral CRD-4730 in capsule form

  • PlaceboDrug

    Placebo to match CRD-4730 in capsule form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline to Day 22
  2. Changes in Laboratory AssessmentsTime frame: Baseline to Day 15
  3. Changes in Vital Signs Measurement: Systolic and Diastolic blood pressureTime frame: Baseline to Day 15
  4. Changes in Vital Signs Measurement: Pulse RateTime frame: Baseline to Day 15
  5. Changes in Vital Signs Measurement: Respiratory RateTime frame: Baseline to Day 15
  6. Changes in Vital Signs Measurement: Body TemperatureTime frame: Baseline to Day 15
  7. Changes in Physical ExamTime frame: Baseline to Day 22
  8. Changes in Electrocardiogram (ECG) MeasurementsTime frame: Baseline to Day 22

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic Children's Hospital

    Cleveland, Ohio

  • Baylor College of Medicine

    Houston, Texas

  • Stollery Children's Hospital University of Alberta

    Edmonton, Alberta, Canada

  • University of British Columbia (UBC) Hospital

    Vancouver, British Columbia, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • University of Western Ontario

    London, Ontario, Canada

  • Hôpital Louis Pradel

    Bron, France

  • Groupe Hospitalier Bichat Claude Bernard

    Paris, France

  • Hôptal Nord Laennec

    Nantes, Loire-Atlantique, France

  • IRCCS Pavia Istituti Clinici Scientifici Maugeri Spa Società Benefit

    Pavia, Lombardy, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.